Company Overview and News

38 firms record 205 director share purchases worth HK$252m, against 17 firms with 92 disposals worth HK$102m

2017-05-21 scmp
Several combo purchases, with acquisitions by two former directors in Country Garden Holdings and two non-execs at CLP Holdings

Corporate shareholder trading quiet ahead of reporting season

2017-02-12 scmp
With the busy reporting period running from February to April, directors and listed-firms are prohibited from trading one to two months prior to the announcement of results

Hong Kong company stock buying high for third week amid heavy trade in blue chips

2016-11-20 scmp
The buying was high for the third straight week while the selling among directors rebounded based on filings on the Hong Kong stock exchange from November 14 to 18. A total of 34 companies recorded 196 purchases worth HK$356 million versus 13 firms with 38 disposals worth HK$52 million. The number of companies on the buying side was not far off from the previous week’s 38 firms while the number of trades was up from the previous week’s 168 acquisitions.

Improve Your Returns With These 3 Great Foreign Stocks

2016-09-18 seekingalpha
I am trying to provide good statistical picks. These are stocks that are likely to outperform the market. This is different from most stocks you read about on this site: high conviction picks. Most of these articles underestimate the factor chance, or luck, in the game of investing. Unfortunately this factor is very important in investing. Each time when we are buying or selling a stock we are just rolling a dice.

Playmates Toys: Unknown, Undervalued, Misunderstood

2016-01-26 seekingalpha
Playmates Toys has a history of strong profitability.The company has retained the TMNT toy license for over 30 years - they remain the clear choice for toy manu

Related Articles

SGMO: Sangamo BioSciences and Research Report

2018-05-19 - Asif

OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...

HMNY: Helios and Matheson Analytics and Research Report

2018-05-19 - Asif

Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...

BSTG: Biostage Analysis and Research Report

2018-05-17 - Asif

Overview Biostage is a biotechnology company developing bioengineered organ implants based on its novel CellframeTM technology. The company's Cellframe technology is comprised of a biocompatible scaffold that is seeded with the recipient’s own stem cells. This technology is being developed to treat life-threatening conditions of the esophagus, trachea or bronchus with the objective of dramatically improving the treatment paradigm for those patients. The company believe that its Cellframe technology will provide surgeons with new ways to address damage to the esophagus, bronchus, and trachea due to congenital abnormalities, cancer, infection or trauma. Products being developed based on its Cellframe technology for those indications are called CellspanTM products. The company announced favorable preliminary pre-clinical results of large-animal studies for the esophagus, trachea and bronchus in November 2015. Since then, the Cellspan esophageal implant product candidates hav...